Department of Justice Revises Prosecution Policies, Confirms Importance of Effective Compliance Plans
February 1, 2007
This article, which appears here with permission from The Society of Corporate Compliance & Ethics, was first published in February 2007 in Compliance & Ethics Magazine. Please contact marlene.robinson@corporatecompliance.orgto reprint or copy this article.
Author(s)
Related Insights
July 22, 2025
Health Care Law Today
GLP-1 Receptor Agonists: Clinical Trial Considerations
The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide (Victoza®), semaglutide (Ozempic®, Wegovy®), and tirzepatide (Mounjaro®, Zepbound®).
July 21, 2025
Energy Current
DOE Announces Pilot Program to Build Advanced U.S. Nuclear Fuel Supply Lines: What You Need to Know Now
Introduction Coming on the heels of its June 2025 announcement establishing a pilot program for reactor construction and operation in…
July 21, 2025
Labor & Employment Law Perspectives
Considering a Reduction in Force? Some Preliminary Considerations
Employers sometimes find it necessary to make the difficult decision to undergo a reduction-in-force (RIF), resulting in employee layoffs…